Repositioning candidate gene approaches in the post-GWAS era: a clinical perspective from psychiatric pharmacogenetics.

Integrating targeted genetic approaches with genome-wide evidence enhances clinical pharmacogenetics in psychiatry, especially for pharmacokinetic and pharmacodynamic traits.

• Why it matters: Despite advances in genomic research, translating these findings into clinical practice remains difficult, limiting personalized treatment options in psychiatric care.
• What they did: The authors advocate for combining candidate gene studies with genome-wide analyses, multi-omics data, and hypothesis-driven research to improve pharmacogenetic strategies, focusing on key genes like CYP2D6 and CYP2C19.
• The result: This integrated approach can bridge the gap between discovery and clinical implementation, enabling more effective precision medicine and better treatment outcomes for psychiatric patients.